Insulin lispro and insulin glulisine have been shown to be equivalent on all glucose infusion measures in patients with type 2 diabetes, with the exception of a 0.5 mmol/l lower glucose excursion with insulin glulisine in type 2 patients with obesity [44]. The gene discussed is INS; the disease is Obesity.